Coherus BioSciences logo

Coherus BioSciences

Redwood City, CA

Coherus BioSciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. Founded in 2010, Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.

coherus.com

Company Details

Founded

2010

Employees

221 employees

Raised

$1,271,227,776

Headquarters Location

Redwood City, CA

Public

Yes

Acquired

No

CEO

Dennis M. LanfearDennis M. Lanfear

Founders

Dennis M. Lanfear
Dennis M. Lanfear
Wolfgang Roehr
Wolfgang Roehr
Steve Glover
Steve Glover

Company Collections

These are collections Coherus BioSciences is a part of. Click on the collection name to view similar companies.

Coherus BioSciences' Tech Stack

Current Job Listings

Listing 0 of 9 job openings

    Coherus BioSciences Headquarters Location

    333 Twin Dolphin Dr suite 600, Redwood City, CA 94065-1442

    Total Amount Raised: $1,271,227,776

    Coherus BioSciences Funding Rounds

    • Post Ipo Equity

      $50,000,000

    • Post Ipo Debt

      $100,000,000

      Post Ipo Debt Investors

      Pharmakon Advisors
    • Post Ipo Debt

      $400,000,000

      Post Ipo Debt Investors

      Armentum Partners
    • Post Ipo Equity

      $1,960,000

      Post Ipo Equity Investors

      Northern Star Partners
    • Post Ipo Equity

      $50,000,000

      Post Ipo Equity Investors

      Shanghai Junshi Biosciences Co
    • Post Ipo Debt

      $75,000,000

      Post Ipo Debt Investors

      Healthcare Royalty
    • Post Ipo Equity

      $6,806,432

    • Post Ipo Equity

      $117,100,000

    • Post Ipo Equity

      $100,000,000

    • Post Ipo Equity

      $100,000,000

    • Post Ipo Equity

      $120,000,000

    • Series C

      $54,700,000

      Series C Investors

      KKR
      Venrock
      RA Capital Management
      Rock Springs Capital
      Lilly Ventures
      Sofinnova Ventures
      Vivo Capital
      Viva Capital Advisors
      F-Prime Capital
      Helix Ventures
      KMG Capital Partners
      Eight Roads
    • IPO

      Unknown

    • Debt Financing

      $28,000,700

      Debt Financing Investors

      Helix Ventures
    • Series B

      $61,500,000

      Series B Investors

      Daiichi Sankyo
      Cook Pharmica
      Medpace
      Lilly Ventures
      Helix Ventures
    • Debt Financing

      $3,794,959

    • Series Unknown

      $865,666

    • Series A

      $1,500,000

      Series A Investors

      Helix Ventures
      Medpace
    Funding info provided by Diffbot.

    Coherus BioSciences Reviews

    0 out of 5 stars

    Based on 0 reviews

    Review data

    Share your thoughts

    Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Coherus BioSciences.

    Recent reviews